aTyr Pharma (NASDAQ:ATYR) Announces Earnings Results

aTyr Pharma (NASDAQ:ATYR) posted its quarterly earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01, FiscalAI reports. The company had revenue of $189.56 million during the quarter.

aTyr Pharma Stock Performance

Shares of aTyr Pharma stock traded up $0.01 during trading hours on Friday, reaching $0.51. The company’s stock had a trading volume of 355,761 shares, compared to its average volume of 1,115,501. aTyr Pharma has a one year low of $0.40 and a one year high of $6.50. The company has a market capitalization of $50.14 million, a P/E ratio of -0.70 and a beta of 0.54. The stock’s fifty day simple moving average is $0.51 and its two-hundred day simple moving average is $0.70.

Analyst Ratings Changes

Several brokerages have recently commented on ATYR. Wall Street Zen upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, July 12th. Freedom Capital raised aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th. Finally, Weiss Ratings downgraded aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Insider Activity

In other aTyr Pharma news, Director Paul Schimmel bought 100,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was bought at an average cost of $0.50 per share, with a total value of $50,000.00. Following the completion of the transaction, the director directly owned 779,143 shares in the company, valued at approximately $389,571.50. The trade was a 14.72% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 5.75% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On aTyr Pharma

A number of hedge funds have recently added to or reduced their stakes in ATYR. California State Teachers Retirement System bought a new stake in aTyr Pharma during the second quarter worth $28,000. Main Street Financial Solutions LLC lifted its stake in aTyr Pharma by 7.0% during the 2nd quarter. Main Street Financial Solutions LLC now owns 143,600 shares of the company’s stock valued at $728,000 after acquiring an additional 9,350 shares in the last quarter. Legal & General Group Plc bought a new position in aTyr Pharma during the 2nd quarter valued at $49,000. Raymond James Financial Inc. boosted its holdings in aTyr Pharma by 79.3% during the 2nd quarter. Raymond James Financial Inc. now owns 24,839 shares of the company’s stock worth $126,000 after acquiring an additional 10,989 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in aTyr Pharma during the 2nd quarter worth $63,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.